159634-59-0

Basic information

• Product Name: N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE
• Synonyms: TERT-BUTYL 3-OXO-2,3-DIHYDROSPIRO[INDENE-1,4'-PIPERIDINE]-1'-CARBOXYLATE;N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE;2,3-Dihydro-3-oxo-spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid tert-butyl ester;tert-butyl 3-oxo-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-car;Spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid, 2,3-dihydro-3-oxo- 1,1-diMethyl ethyl ester;Caboxylate;1'-Boc-3-oxo-2,3-dihydrospiro[indene-1,4'-piperidine];2,3-dihydro-3-oxo-spiro[1H-indene-1,4'-piperidine]-1'-carboxylic acid 1,1-dimethylethyl ester
• CAS NO: 159634-59-0
• Molecular Formula: C₁₈H₂₃NO₃
• Molecular Weight: 301.38
• Mol File: 159634-59-0.mol

Chemical Properties

• Melting Point: 120-122 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• Boiling Point: 439.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.17
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: -0.80±0.20(Predicted)
• CAS DataBase Reference: N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE(159634-59-0)
• EPA Substance Registry System: N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE(159634-59-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 159634-59-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE is used as a key intermediate in organic synthesis for the development of novel chemical entities. Its unique structure allows for the creation of a variety of complex organic molecules, contributing to the advancement of chemical research and innovation.
Used in Drug Discovery:
In the realm of drug discovery, N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE is utilized as a lead compound for the identification and optimization of new therapeutic agents. Its potential biological activities and pharmacological properties make it a valuable asset in the search for effective treatments for various diseases.
Used in Medicinal Chemistry Research:
N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE is employed as a research tool in medicinal chemistry to study its interactions with biological targets and understand its mechanism of action. This knowledge aids in the design and development of more effective and safer drugs.
Used in Pharmaceutical Industry:
N-BOC-1-[4-SPIRO-PIPERIDINE]-3-INDANONE is used as a potential therapeutic agent in the pharmaceutical industry for the treatment of various diseases. Its diverse applications and potential pharmaceutical uses have garnered significant attention in the scientific community, paving the way for further research and development in this area.

Upstream product

• 137419-24-0 1'-(tert-butyloxycarbonyl)spiro<1H-indene-1,4'-piperidine> 
• 13292-87-0 dimethylsulfide borane complex 
• 95-13-6 1-indene 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 185525-42-2 tert-butyl 3-hydroxy-2,3-dihydrospiro[indene-1,4’-piperidine]-1‘-carboxylate 
• 148835-99-8 N-Boc spiroindane 

Downstream Products

• 180465-55-8 spiro[1H-indene-1,4'-piperidin]-3(2H)-one 
• 159634-63-6 Spiro(2-oxo-1,2,3,4-tetrahydroquinoline-4,4'-piperidine) 
• 159634-65-8 2,3-dihydro-1H-spiro[isoquinoline-4,4'-piperidin]-1-one 
• 873056-18-9 1,2,3,4-tetrahydroquinolin-4-spiro-4'-(N'-benzylpiperidine) 
• 873056-16-7 1'-benzyl-spiro[1H-indene-1,4'-piperidin]-3(2H)-one 
• 917898-66-9 1-neopentyl-1'-(2-nitrophenyl)-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinoline] 
• 1138522-08-3 t-butyl 3-hydroxy-3-methyl-2,3-dihydrospiro(indene-1,4'-piperidine)-1'-carboxylate 
• 231938-20-8 spiro[indene-1,4'-piperidin]-3(2H)-one hydrochloride 
• 185525-96-6 C₃₂H₄₁N₃O₆ 
• 185526-08-3 C₃₃H₄₃N₃O₅ 
• 185525-94-4 C₂₈H₃₄N₂O₅ 
• 185525-95-5 C₂₃H₂₆N₂O₃ 
• 185526-66-3 1'-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydrospiro[1H-indene-1,4'-piperidine]-3-acetic acid 

Relevant articles and documents

Novel heterocyclic derivative capable of being used as SHP2 inhibitor

The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2

A series of spiropiperidine carbazoles were synthesized and evaluated as MCHR2 antagonists using a FLIPR assay. The pharmacokinetic properties of selected compounds have also been studied. This effort led to the discovery of potent and specific MCHR2 antagonists. Compound 38 demonstrated good pharmacokinetic properties across rat, beagle dog and rhesus monkey and had a favorable selectivity profile against a number of other receptors. These MCHR2 antagonists are considered appropriate tool compounds for study of the function of MCHR2 in vivo.

NOVEL SPIRO COMPOUND AND MEDICINE COMPRISING THE SAME

It is to provide a novel compound useful for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. A spiro compound represented by the following general for

ANTAGONISTS OF PGD2 RECEPTORS

Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases.

Modulators of muscarinic receptors

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

SPIRO-PIPERIDINE DERIVATIVES

Present invention is concerned with novel indol- 2-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention andlor treatment of anxiety and depressive disorders and other diseases. The compounds of present invention have the general Formula (I) wherein R1 to R 11 and X are as defined in the description

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

Spiropiperidine derivatives

A compound of the formula (I) wherein R1and R2is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group. A is CH2, CO or SO2. B is a single bond, alkylene or alkenylene. D is O or S. E is alkylene or alkenylene. wherein G is a substituted or unsubstituted cycloalkene ring, or a substituted cycloalkane ring. Ar is a substituted or unsubstituted aryl ring, or a substituted or unsubstituted heteroaryl ring. R3is alkyl. n is 1-3. The invention includes a pharmacologically acceptable salt, ester or other derivative of a compound of the formula (I). The invention also provides pharmaceutical compositions and methods of treating specified diseases utilizing a compound of formula (I).